Frazier Lifesciences Acquisition Corporation
Status: Deal Closed
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $138.00M |
|---|---|
| IPO Date | Dec 9, 2020 |
| CEO | James N. Topper, M.D., Ph.D. |
| Left Lead | Credit Suisse |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector |
Healthcare
Biotechnology |
| IPO Geography | Global |
| Target Company | NewAmsterdam Pharma |
| Deal Announced | Jul 25, 2022 |
| Deal Size, $M | $326.00M |
| Deal Sector | Healthcare |
| Deal Geography | Europe |
| SEC Filings | www.sec.gov |
| Approval Vote | Nov 15, 2022 |
| Amendment Vote | TBD |
| Closing Date | Nov 22, 2022 |
Formerly FLAC
NAMS
NAMSW
| Price | $20.10 |
|---|---|
| Last closing price | $23.68 |
| H/L, today | $19.59 / $22.44 |
| H/L, 52-week | $5.63 / $32.87 |
| Volume, today | 3,012,391 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Frazier Lifesciences Acquisition Corporation:
- Structure and cap table
- 8 directors & officers
- 20 filings and events
- 1 underwriters
- 9 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| James N. Topper, M.D., Ph.D. | 58 | Chief Executive Officer and Chairman |
| David Topper | 63 | Chief Financial Officer and Director |
| Gordon Empey | 52 | Vice President and General Counsel |
| Max M. Nowicki, M.D. | 31 | Vice President, Acquisitions |
| Robert F. Baltera | 55 | Director |
| Michael F. Bigham | 63 | Director |
| Carol G. Gallagher, Pharm.D. | 56 | Director |
| Krishna R. Polu, M.D. | 47 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Credit Suisse | BR | 12,000,000 | units |
| 12,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.